5 Potentially Practice-Changing Trials | Medical News | ESC 2026

•⁠ ⁠REACT: Subclinical atherosclerosis starts early — silent plaque detected in ~1 in 13 adults aged 18–29, supporting earlier prevention and opportunistic CT detection.
•⁠ ⁠AIR-STEMI: In STEMI with multivessel CAD, angiography-derived FFR to guide non-culprit PCI reduced MACE by 38% and complications by 37% vs angiography guidance.
•⁠ ⁠TAVI PCI: In patients needing both procedures, PCI after TAVR was as safe as PCI before TAVR, particularly when severe AS is driving the clinical picture and there is no acute coronary indication for PCI first , allowing greater flexibility in treatment sequencing.
•⁠ ⁠CRHCP: More intensive BP control was associated with lower dementia/neurodegenerative disease risk, reinforcing BP control as both cardiovascular and brain protection.
•⁠ ⁠STAREE: In adults ≥70 years without known CVD, diabetes, or dementia, atorvastatin for primary prevention reduced major CV events by ~30%, but without demonstrated mortality benefit.

https://www.escardio.org/news/news-room/congress-news/

4 Views